Press Release Details

Mersana Therapeutics to Present Poster at the 2015 San Antonio Breast Cancer Symposium

November 30, 2015

CAMBRIDGE, Mass., Nov. 30, 2015 -- Mersana Therapeutics, Inc. today announced that it will present a poster at the 2015 San Antonio Breast Cancer Symposium, taking place December 8-12, 2015, at the Henry B. Gonzalez Convention Center in San Antonio, TX.

The poster details are as follows:
Date: Friday, December 11, 2015
Time: 7:30 a.m. – 9:00 a.m. CST

Title: XMT-1522 Induces Tumor Regressions in Pre-Clinical Models Representing HER2-Positive and HER2 Low-Expressing Breast Cancer
Abstract Number: P4-14-28
Poster Session: Poster Session 4, HER2-Targeted Therapy
Presenter: Donald A. Bergstrom, M.D., Ph.D., Chief Medical Officer, Mersana Therapeutics

XMT-1522, Mersana’s lead product candidate, is a novel HER2-targeting therapy based on Mersana’s Fleximer® immunoconjugate technology that carries an average of 15 proprietary auristatin payload molecules.

The annual Symposium provides a forum for sharing new breast cancer insights and data. The meeting is sponsored by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research and Baylor College of Medicine. For more information, visit

About Mersana Therapeutics                                     

Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit

Media Contact
6 Degrees
Tony Plohoros
(908) 591-2839

Investors Contact
Stern Investor Relations, Inc.
Jesse Baumgartner
(212) 362-1200